Compare · RMD vs VVOS
RMD vs VVOS
Side-by-side comparison of ResMed Inc. (RMD) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $31.49B, about 549.6x VVOS ($57.3M).
- Over the past year, RMD is down 6.1% and VVOS is down 69.0% - RMD leads by 63.0 points.
- VVOS has been more active in the news (7 items in the past 4 weeks vs 2 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- ResMed Inc.
- Vivos Therapeutics Inc.
- Price
- $219.82+0.11%
- $0.83-4.46%
- Market cap
- $31.49B
- $57.3M
- 1M return
- -2.86%
- -25.78%
- 1Y return
- -6.09%
- -69.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 7
- Recent ratings
- 25
- 1
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.
Latest VVOS
- Vivos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Reports Full Year 2025 Financial Results
- Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
- SEC Form 3 filed by new insider V-Co Investors 3 Llc
- Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 4 filed by Skaff Michael C
- SEC Form NT 10-K filed by Vivos Therapeutics Inc.